相关实验视频
Updated: Jul 2, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
与可变速率胰岛素输注糖尿病酸性糖尿病治疗方案相关的结果
Anojian Koneshamoorthy1, Dilan Seneviratne Epa1, David N O'Neal2
1Department of Endocrinology & Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Victoria 3065, Australia.
Journal of diabetes and its complications
|February 22, 2024
概括
可变速率静脉注射胰岛素输注 (VRIII) 有效治疗糖尿病酸性 (DKA),实现快速血糖控制,降低血糖的风险最小. 然而,由于治疗期间低血的高发病率,仔细监测的水平至关重要.
科学领域:
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
- 关键护理医学 关键护理医学
背景情况:
- 糖尿病酸症 (DKA) 是糖尿病的一种严重并发症,需要及时治疗.
- 变速静脉注射胰岛素输注 (VRIII) 是DKA的标准治疗方法.
- 了解葡萄糖校正率与不良事件之间的关系对于优化DKA治疗方案至关重要.
研究的目的:
- 调查VRIII期间葡萄糖校正率与患有DKA的成年患者不良事件发生率之间的关联.
- 评估VRIII在实现血糖控制和解决酸性症方面的安全性和有效性.
主要方法:
- 在2012年至2017年期间,对97名患有DKA的成人患者进行了回顾性观察性研究,这些患者接受了VRIII治疗.
- 分析了葡萄糖和水平,pH值和临床结果.
- 用回归分析来评估早期高血糖纠正 (<10 mmol/L) 与低血糖 (<4.0 mmol/L) 和低血糖 (<3.3 mmol/L) 等不良事件之间的关系.
主要成果:
- 在大多数患者 (88%在24小时内) 中,VRIII协议成功地实现了早期高血糖纠正.
- 低血糖率很低 (在12小时内6.2%,在24小时内8.2%).
- 低血发生在40.2%的患者中,与较低的pH值有关,但与葡萄糖校正率没有直接关联.
结论:
- 该VRIII协议是有效的快速纠正高血糖和解决DKA的低血糖的风险.
- 低血的高发病率需要积极的替代策略,特别是在显著酸性病的患者中.
- 这些发现支持VRIII的持续使用,同时强调了警的电解质监测和管理的重要性.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
172
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
172
Insulin Formulations: Types and Delivery
196
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
196
Hypoglycemia and Glucagon
262
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
262
One-Compartment Model: IV Infusion
198
Intravenous (IV) infusion is often utilized when continuous and controlled drug delivery is necessary, such as during surgery or in the treatment of chronic diseases. This method offers numerous advantages, including immediate drug action, precise control over dosage, and bypassing the first-pass metabolism.
The one-compartment model for IV infusion uses mathematical equations to describe the rate of change in drug quantity in the body. At steady-state or infusion equilibrium, the drug input...
The one-compartment model for IV infusion uses mathematical equations to describe the rate of change in drug quantity in the body. At steady-state or infusion equilibrium, the drug input...
198
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Diabetes: Management and Pharmacotherapy
283
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
283

